Skip to main content

Table 6 Initial and long-term treatment of VTE among all cancer patients

From: Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study

 

VTE (algorithm 1#)

VTE (algorithm 2&)

(N = 1,388)

(N = 473)

Initial treatment

Patient no. (%)

Patient no. (%)

Thromboectomy

7 (0.5)

7 (1.5)

Low molecular weight heparin (LMWH)

  

  LMWH alone

58 (4.2)

64 (13.5)

  LMWH + warfarin

143 (10.3)

148 (31.3)

Unfractioned heparin (UFH)

  

  UFH alone

79 (5.7)

115 (24.3)

  UFH + warfarin

72 (5.2)

77 (16.3)

UFH + LWMH

  

  UFH + LMWH

16 (1.1)

17 (3.6)

  UFH + LMWH + warfarin

43 (3.1)

45 (9.5)

Warfarin only

49 (3.5)

0 (0.00)

No anticoagulation therapy

921 (66.4)

0 (0.00)

Long-term treatment

Patient no. (%)

Patient no. (%)

LMWH alone

-

24 (5.8%)

UFH alone

-

24 (5.8%)

Warfarin alone

-

192 (46.3%)

LMWH + warfarin

-

13 (3.1%)

UFH + warfarin

-

10 (2.4%)

LMWH and UFH

-

3 (0.7%)

No anticoagulant therapy

-

149 (35.9%)

  1. #VTE algorithm 1 was defined as a hospital admission with diagnostic codes of VTE (ICD-9-CM codes 415.1x, 451.xx, 452, and 453.xx).
  2. &VTE algorithm 2 was based on both the hospital admission with diagnostic codes of VTE and managements of VTE (prescription of intravenous or subcutaneous (IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)) or reimbursement codes of surgical thromboectomy) during the hospital stay.